Caplin Point Laboratories Limited (CAPLIPOINT)
Valuation Rating
Score: 17/100
Valuation Overview
| P/E Ratio | 30.779537 |
| P/B Ratio | 5.9160933 |
| Dividend Yield | 28.000000000000004% |
| Current Price | ₹2159.8 |
| DCF Value | ₹365.1739048120106 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹2159.8 |
| DCF Value | ₹365.1739048120106 |
| Graham Value | ₹877.125 |
| DDM Value | ₹86.57142857142857 |
| Earnings Value | ₹1086.4239063259108 |
| Average Value | ₹567.4919067700798 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | 17.5% |
| Revenue Growth | 10.4% |
| Market Cap | ₹16417.01 Cr |
Valuation Analysis Score: 17/100
Undervaluation Score: 17/100
Valuation Score: 10/30
Growth Score: 7/30
Intrinsic Value Score: 0/40
Growth Score: 7/30
Intrinsic Value Score: 0/40
Key Analysis Points:
- Excellent operating margins above 20%
- Good growth confidence score above 60%
Recommendation
Caution - Stock may be overvalued, detailed analysis recommended
Detailed Metrics
Current Price: ₹2,159.80
Operating Margins: 30.1%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 61.4%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-06-03 05:23:33